$Barinthus Biotherapeutics (BRNS.US)$
Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update
11 minutes ago, 5:00 AM PST
Via GlobeNewswire
BRNS
Share
• Prioritizing VTP-1000 development in celiac disease, Phase 1 data expected in mid-2025
• Postponing further clinical development of VTP-300 in chronic hepatitis B (CHB) until a partner is identified
• Extending the cash runway to the start of 2027 by reducing costs, including an approxim...

$Barinthus Biotherapeutics (BRNS.US)$
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
Arbutus Biopharma and Barinthus Bio announced new preliminary data from Phase 2a IM-PROVE II trial showing enhanced results when combining imdusiran, VTP-300, and low-dose nivolumab in treating chronic hepatitis B virus. 23% of participants receiving this combination achieved HBsAg l...

$Barinthus Biotherapeutics (BRNS.US)$
Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences
Barinthus Biotherapeutics (NASDAQ: BRNS) announced that updated clinical data from its chronic hepatitis B program will be presented at The Liver Meeting® 2024 in San Diego. The late-breaking presentation will focus on VTP-300 combined with low-dose nivolumab and its association with HBsAg loss in specific chronic hepatitis B patien...

$Barinthus Biotherapeutics (BRNS.US)$ •In the fourth quarter of 2024, the Company expects to:
◦VTP-300 (HBV):
▪Announce updated interim data from HBV003, our Phase 2b trial evaluating additional dosing of VTP-300 and timing of PD-1 inhibition, in people with CHB on NUC therapy.
▪Announce updated interim data from the Phase 2a AB-729-202 clinical trial evaluating the combination of VTP-300 and Arbutus’ imdusiran, in people with CHB on NUC therapy.

$Barinthus Biotherapeutics (BRNS.US)$
Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer
• Investigational immunotherapy, VTP-300, is being evaluated as part of a potential functional cure regimen for chronic Hepatitis B.
• Interim data update for HBV003 anticipated in Q4 2024.
• Data update for PCA001 anticipated in H1 2025.
OXFORD, United Kingdom, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Barinthus B...

$Barinthus Biotherapeutics (BRNS.US)$
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
Barinthus Biotherapeutics announced plans to prioritize its pipeline, focusing on VTP-300 for Chronic Hepatitis B (CHB) and VTP-1000 for celiac disease, following positive interim data from ongoing Phase 2 trials. The company will restructure, reducing its workforce by 25%, and expects to extend its cash runway to ...

$Arbutus Biopharma (ABUS.US)$ $Barinthus Biotherapeutics (BRNS.US)$ Arbutus Biopharma (ABUS) said Thursday data from a phase 2a trial in patients with chronic hepatitis B virus infection showed that treatment with imdusiran followed by Barinthus Biotherapeutics' (BRNS) VTP-300 was generally safe and well-tolerated.
Based on preliminary end-of-treatment data, Arbutus said that the therapy resulted in maintenance of lower hepatitis B surface antigen levels during the post-treatment follow-up period.
...

$Barinthus Biotherapeutics (BRNS.US)$ Barinthus Bio To Present VTP-300 Clinical Updates At EASL Congress 2024
Two abstracts highlighting the Company's lead hepatitis B-focused asset will be presented as poster and oral presentations.
More mature interim data to be presented at EASL following abstract data cuts earlier in the year may indicate potential rates of functional cure.